Trial Condition(s):

Carcinoma, Renal Cell

Study to observe safety and efficacy of Nexavar in treatment of kidney cancer (POWER-NEXT)

Bayer Identifier:

15246

ClinicalTrials.gov Identifier:

NCT01353794

EudraCT Number:

Not Available

Terminated/Withdrawn

Trial Purpose

The objective of this Non-Interventional study is to evaluate the effectiveness & safety of Nexavar in advanced Renal Cell Carcinoma (RCC) patients under daily-life treatment conditions based on age of the patient (older (age >70 years) and younger patients (age <70 years). Specifically investigated are the tumor status, duration of Nexavar ® treatment (number of cycles) and incidence of Hand foot Skin Reaction.

Inclusion Criteria
- Patients with diagnosis of advanced Renal Cell Carcinoma (RCC) and decision taken by the investigator to prescribe Sorafenib
Exclusion Criteria
- Exclusion criteria must be read in conjunction with the local product information.

Trial Summary

Enrollment Goal
0
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
No

Where to Participate

Locations
Status
LocationsStatus

Trial Design